Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology
Top Cited Papers
- 13 March 2007
- journal article
- review article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 112 (8) , 417-428
- https://doi.org/10.1042/cs20060342
Abstract
The intracellular signal transduction of AngII (angiotensin II) has been implicated in cardiovascular diseases, such as hypertension, atherosclerosis and restenosis after injury. AT1 receptor (AngII type-1 receptor), a G-protein-coupled receptor, mediates most of the physiological and pathophysiological actions of AngII, and this receptor is predominantly expressed in cardiovascular cells, such as VSMCs (vascular smooth muscle cells). AngII activates various signalling molecules, including G-protein-derived second messengers, protein kinases and small G-proteins (Ras, Rho, Rac etc), through the AT1 receptor leading to vascular remodelling. Growth factor receptors, such as EGFR (epidermal growth factor receptor), have been demonstrated to be ‘trans’-activated by the AT1 receptor in VSMCs to mediate growth and migration. Rho and its effector Rho-kinase/ROCK are also implicated in the pathological cellular actions of AngII in VSMCs. Less is known about the endothelial AngII signalling; however, recent studies suggest the endothelial AngII signalling positively, as well as negatively, regulates the NO (nitric oxide) signalling pathway and, thereby, modulates endothelial dysfunction. Moreover, selective AT1-receptor-interacting proteins have recently been identified that potentially regulate AngII signal transduction and their pathogenic functions in the target organs. In this review, we focus our discussion on the recent findings and concepts that suggest the existence of the above-mentioned novel signalling mechanisms whereby AngII mediates the formation of cardiovascular diseases.Keywords
This publication has 121 references indexed in Scilit:
- Angiotensinergic stimulation of vascular endothelium in mice causes hypotension, bradycardia, and attenuated angiotensin responseProceedings of the National Academy of Sciences, 2006
- Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidneyProceedings of the National Academy of Sciences, 2006
- Angiotensin II stimulates phosphorylation of an ectodomain-truncated platelet-derived growth factor receptor-β and its binding to class IA PI3K in vascular smooth muscle cellsBiochemical Journal, 2006
- Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activationProceedings of the National Academy of Sciences, 2006
- Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II – editorial reviewCurrent Opinion in Nephrology and Hypertension, 2005
- ADAM Binding Protein Eve-1 Is Required for Ectodomain Shedding of Epidermal Growth Factor Receptor LigandsPublished by Elsevier ,2004
- PACSIN3 Binds ADAM12/Meltrin α and Up-regulates Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth FactorPublished by Elsevier ,2003
- Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivationBiochemical and Biophysical Research Communications, 2002
- ATRAP, Novel AT1 Receptor Associated Protein, Enhances Internalization of AT1 Receptor and Inhibits Vascular Smooth Muscle Cell GrowthBiochemical and Biophysical Research Communications, 2000
- G-Protein and Tyrosine Kinase Receptor Cross-Talk in Rat Aortic Smooth Muscle Cells: Thrombin- and Angiotensin II-Induced Tyrosine Phosphorylation of Insulin Receptor Substrate-1 and Insulin-like Growth Factor 1 ReceptorBiochemical and Biophysical Research Communications, 1996